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Normal epithelial thyroid cells in culture are inhibited by TGF-β1. Instead, transformed thyroid cell lines are frequently resistant
to its growth inhibitory effect. Loss of TGF-β responsiveness could be due to a reduced expression of TGF-β receptors, as shown
in transformed rat thyroid cell lines and in human thyroid tumors, or to alterations of other genes controlling TGF-β signal
transduction pathway. However, in thyroid neoplasia, a complex pattern of alterations occurring during transformation and
progression has been identified. Functionally, TGF-β1 acts as a tumor suppressor in the early stage of transformation or as a tumor
promoter in advanced cancer. This peculiar pleiotropic behaviour of TGF-β may result from cross-talk with signalling pathways
mediated by other growth factors, among which EGF-like ligands play an important role. This paper reports evidences on TGF-β1
and EGF systems in thyroid tumors and on the cross-talk between these growth factors in thyroid cancer.
1. Introduction
Thyroid gland homeostasis is maintained through a fine
regulation of thyrocyte growth and differentiation. This
regulation occurs through complex interactions between
thyroid-stimulating hormone (TSH) and other growth
factors and cytokines [1]. Evidence supports the role of
transforming growth factor-beta 1 (TGF-β1) and epidermal
growth factor- (EGF-) like ligands in the regulation of
thyroid proliferation and differentiation, given the numerous
information focused on mechanism of signal transduction
and cross-talk. It is emerging the concept that the basis
behind the pleiotropic nature of TGF-β in the context of cell-
type and tumorigenesis derived probably from differences in
the mechanism of such cross-talk.
The TGF-β superfamily, which includes TGF-βs, activins,
and bone morphogenetic proteins (BMPs), is a multi-
functional dimeric proteins family that regulates growth,
differentiation and extracellular matrix production in many
different cell types [2]. In epithelial cells, TGF-β acts as
a tumor suppressor by inhibiting cell growth or by regulating
cellular differentiation or apoptosis.
EGF is the prototype of a large family of peptides that
consists of about a dozen members and has an essential role
in embryonic development as well as in inducing cell growth.
Mutations in the kinase domain of EGFR/ErbB1 (epidermal
growth factor receptor) and ErbB2 are responsible of ligand-
independent activation of cytoplasmic signal transducers
that regulate motility, adhesion, protection from apoptosis,
and transformation [3].
TGF-β and EGF are physiological regulators of thyroid
cell differentiation and proliferation. TGF-β is normally
expressed and secreted by thyrocytes, acting as a potent
inhibitor of thyroid cell growth [4]. EGF, instead, acts
as a strong mitogen for follicular thyroid cells [5]. Any
alterations of these two factors or their signalling pathways
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may play an important role in the stepwise transition
towards malignancy, including the ability to become, at
least partially, resistant to growth inhibition, to proliferate
without dependence on growth factors, to replicate without
limit, to invade, and tometastasize. TGF-β1 appears to have a
dual effect in tumorigenesis. It can act as a tumor suppressor
in the pretumor stage, and as a tumor promoter in late stage
of tumorigenesis. It is likely that during tumorigenesis, as
a result of genetic and/or epigenetic changes, the balance
between those opposing functions of TGF-β1 changes result-
ing in a switch to tumor promotion; however, the precise
mechanism for this switch remains to be clarified [6]. In this
paper we focused our attention on the role of EGF and TGF-
β in the control of proliferation and differentiation of thyroid
cells.
2. Thyroid Cell Regulation by Growth Factors
Physiological regulation of thyroid cell growth and function
involves a complex network of factors that act through
endocrine, paracrine, or autocrine mechanisms. The pro-
liferation and differentiation of thyroid epithelial cells are
under the control of a positive systemic signal, TSH, and a
negative locally produced signal, TGF-β. The main function
of the thyroid is the formation, storage, and secretion of
thyroid hormones tightly controlled by TSH, but requiring
insulin/insulin-like growth factor I (IGF-I) [7]. The steps
leading to the thyroid hormone formation include thy-
roglobulin (TG) synthesis and transport to the lumen of
thyroid follicles, the iodide uptake by the sodium iodide
symporter (NIS), iodination of TG, and coupling of TG
iodotyrosine residues by the thyroperoxidase (TPO). In rat
thyroid cells, the expression of the TG, TPO, NIS, and TSH
receptor (TSHR) is under the control of thyroid-restricted
transcription factors, such as thyroid transcription factor-1
(TTF-1) [8], that plays the most important role in the
expression of all the genes, Pax-8, and TTF-2 [9, 10].
TSH, through the activation of its receptor, has been
shown to stimulate more than one signal transduction
pathway, the main of which being the adenylcyclase/cAMP
(cyclic adenosine monophosphate) pathway. cAMP seems to
account for the mitogenic effects of TSH in human thyroid
cells, mediated by the activation of cAMP-dependent protein
kinases [11]. TSH-induced cAMP also appears to play a
central role in iodide uptake and metabolism in the dog
follicular cells [12], in TG and TPO gene expression in rat
follicular cells [13]. Although TSH is the major regulator
of thyroid growth and functions, it has been shown that
a number of growth factors affect the proliferation and
function of thyroid epithelial cells. In fact, TSH effects can
be potentiated by several growth factors such as insulin
and IGF-I in rat thyroid cells in culture [14]. Insulin or
IGF-I synergizes with TSH to induce thyroid cell growth
and to maintain specialized cell functions [11]. There is
evidence that TSHR and TG gene expression are regulated by
insulin/IGF-I as well as TSH in a rat thyroid cell line (FRTL-
5) [15, 16]. Moreover, an important regulator of thyroid
growth that stimulates proliferation in vitro includes EGF.
3. Epidermal Growth Factor-Related
Ligands and Their Receptors
EGF is the prototype of a large family of peptides structurally
related by possessing an EGF-like domain that consists of 6
cysteine residues capable of forming three disulfide-bonded
intramolecular loops. These ligands are expressed in the
extracellular domain of transmembrane proteins and are
generated by regulated proteolysis to yield growth factors
that contain 49–85 amino acids. The components of the
EGF-like growth factors family are functionally related on the
basis of binding to the members of the tyrosine kinase ErbB
family (EGFR/ErbB1, ErbB2, ErbB3, and ErbB4) and are
divided into three groups: the first includes EGF, transform-
ing growth factor-alpha (TGF-α) and amphiregulin, which
all bind specifically to EGFR/ErbB1. A second group includes
betacellulin, heparin-binding EGF (HB-EGF), and epireg-
ulin binding to both EGFR/ErbB1 and ErbB4, while the third
group comprises the neuregulin family, differentiated by
their binding to ErbB3 and ErbB4 (NRG1 and NRG2) or only
to ErbB4 (NRG3 and NRG4) [17]. All four human receptors
share four extracellular domains with high structural homol-
ogy, a single transmembrane spanning helix, and a cyto-
plasmic portion that contains a conserved but not equally
functional tyrosine kinase domain. Only the EGFR/ErbB1
and ErbB4 are fully functional in terms of ligand binding and
kinase activity. ErbB2 fails to bind any of the known ErbB
ligands but contributes its potent kinase activity to all possi-
ble heterodimers. ErbB3 has an impaired kinase activity and
relies on the kinase activity of its heterodimerization partners
for activation. Heterodimers of ErbB2 and ErbB3 are the
most potent ErbB pair in mitogenic signalling [17–19].
After ligand binding, ErbB receptors achieve activation
by forming homo- or heterodimeric receptor complexes. The
dimerization of ErbB receptors represents the most impor-
tant mechanism that drives transformation. Dimeric recep-
tors become catalytically active and are able to phosphorylate
the cytoplasmic receptor domain that serves as docking
site for a variety of signalling molecules whose recruitment
leads to the activation of intracellular pathways controlling
diverse genetic programs. The two major signalling pathways
activated by ErbB receptors are themitogen-activated protein
kinases (MAPKs) pathway which stimulates proliferation,
and Phosphatidylinositol 3-kinases/AKT (PI3K-AKT) path-
way which promotes cell survival (Figure 1). The specific
combination of ErbB receptors in the dimer defines the
downstream signalling network as well as the intensity and
the duration of the stimulation. Indeed, heterodimers that
involve ErbB3 stimulates the activation of PI3K pathway
[20].
Amplification, overexpression and gene mutation of
EGFR/ErbB1 and ErbB2 have been found in various human
cancers [17, 21]. EGFR/ErbB1 is overexpressed in blad-
der, breast, head and neck, kidney, nonsmall cell lung,
and prostate cancers [22]. Three truncated forms of the
EGFR/ErbB1 have been described [23] among which the
EGFRvIII (variant III) lacks the majority of the ectodomain
and does not bind EGF. This variant is the most common
in glioblastoma multiforme and also occurs in lung, breast,
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Figure 1: Mechanisms of action of ErbB receptor. In tumor cells, ErbB receptor tyrosine kinases are activated by autocrine or paracrine
production of EGF family ligands. Autocrine ligand production results from the activation of G-protein coupled receptors (GPCRs)
or frizzled (FZD) receptor which causes the metalloproteinases-mediated cleavage and release of pro-EGF-related ligands (ectodomain
shedding). Binding of ligands to the extracellular domain of ErbB receptors leads to receptor dimerization, autophosphorylation, and
activation of several downstream signalling pathways. In particular, tyrosine-phosphorylated ErbB receptors bind the adaptor proteins Shc
and Grb2 leading to Sos recruitment and Ras/MAPK pathway activation. The PI3K/Akt pathway is stimulated through recruitment of the
p85 adaptor subunit of PI3K to the receptor.
ovarian, and prostate cancer [24]. ErbB2 protein is overex-
pressed in breast cancer due to gene amplification in 15%–
30% of invasive ductal breast cancers and overexpression
correlates with poor prognosis and disease progression [25].
A number of studies have shown mutations in the kinase
domain of EGFR/ErbB1 and ErbB2 [3, 21]. Intragenic
somatic mutations in the ErbB2 gene were reported in 5% of
nonsmall cell lung cancer, 5% of gastric carcinomas, 3% of
colorectal carcinomas, and 5% of breast carcinomas [26–28].
Accumulating evidence has suggested that also ErbB3 plays a
critical role in cancer. Overexpression of ErbB3 often accom-
panies EGFR/ErbB1 or ErbB2 overexpression and has been
frequently detected in a variety of cancers, including those
of the breast [29], colon [30], stomach [31], ovary [32], and
pancreas [33]. In ErbB2-driven cancers, ErbB3 functions as
an intimate signalling partner that promotes the transform-
ing potency of ErbB2, usually by activating the PI3K/AKT
pathway [34]. ErbB4 receptor is made in at least four
different full-length isoforms as a consequence of alternative
mRNA splicing [35]. It has both oncogenic and tumor sup-
pressive functions. Supporting a role in promoting growth,
overexpression of ErbB4 enhances growth of human breast
cancer cells [36] and transforms mouse mammary epithelial
cells to form tumors in vitro and in vivo [37]. Supporting a
suppressive role for mammary tumor growth activation of
ErbB4 in breast cancer cells has been associated with cell-
cycle arrest, differentiation, and apoptosis in vitro [38].
4. Epidermal Growth Factor-Related
Ligands and Their Receptors in Thyroid
EGF is synthesized by thyroid gland and is able to induce
thyroid cell proliferation in several species together with
the loss of thyroid specific functions [5]. Moreover, EGF
enhances the migration and invasiveness of papillary thyroid
cancer [5, 39–41]. Accordingly, in vitro growth was inhibited
when either neutralizing anti-TGF-α or anti-EGFR/ErbB1
antibodies were applied to thyroid carcinoma cell lines [42].
A correlation between the staining intensity of EGF and
recurrence has been found statistically significant in a set
of human papillary thyroid tumors, indicating EGF as a
predictor of papillary thyroid carcinoma aggressiveness [43].
Follicular epithelial thyroid cells expressed weakly TGF-α
protein, whereas 66% of hyperplastic thyroid nodules, 100%
of thyroid adenocarcinomas, and all cases of papillary, fol-
licular, and medullary carcinomas displayed intense staining
for TGF-α. A parallel pattern of staining was observed for the
EGFR/ErbB1 in these tissues, suggesting the potential for an
in vivo autocrine loop [44]. Papillary carcinomas and their
lymph node metastases coexpressed EGFR/ErbB1 and EbB2
mRNA transcripts at a higher level than in normal thyroid
tissues [45]. Moreover, in the same histotype of cancer, it
has also been demonstrated the coexpression of TGF-α and
EGFR/ErbB1 mRNA transcripts at higher levels than in non-
neoplastic thyroid tissues [46].
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Rat thyroid epithelial cells transformed with K-ras onco-
gene were found to express high levels of ErbB4 receptor
and Neuregulin-1 (HRG/NDF/NRG1) ligand compared to
rat thyroid epithelial control cells. Treatment of K-ras
transformed thyroid cells with neutralizing antibody against
NRG1 reduced by 50% cell proliferation, demonstrating
the presence of an active NRG1 protein secreted in the
supernatant by the cells. These data indicate that in K-
ras rat thyroid epithelial cells, the growth factor NRG1
signals through the heterodimer ErbB2/ErbB4 receptors in
an autocrine fashion [47]. Nevertheless, in human pap-
illary carcinomas the protein overexpression and nuclear
localization of the NRG1 precursor isoform compared to
normal thyroid tissues was not associated with the expression
of ErbB receptors, while the expression of neuregulin-
β3 (Hrgβ3) was significantly correlated to ErbB3 protein
expression, indicating this receptor as the cognate one
[48].
EGFR/ErbB1 was higher expressed in anaplastic and pap-
illary thyroid cancers than in normal thyroid tissues. In par-
ticular, Bergstrom et al. [49] have shown that EGFR/ErbB1
was expressed in all six anaplastic thyroid carcinomas exam-
ined and it was constitutive phosphorylated in 3 of the 6 cell
lines tested. Song [50] has demonstrated that EGFR/ErbB1
was expressed in 90% of papillary carcinomas analyzed.
Moreover, the role of EGFR/ErbB1 in stimulating the growth
of thyroid tumors has been highlighted by the capability
of Gefitinib, a small molecule inhibitor of EGFR/ErbB1, to
reduce the growth of papillary, follicular, and anaplastic thy-
roid cancer cells [51, 52]. By immunohistochemical analyses,
cytoplasmic immunopositivity of EGFR/ErbB1 was observed
in papillary carcinomas, while no nuclear positivity for EGF
and EGFR/ErbB1 was demonstrated. A study by Akslen et al.
significantly associated cytoplasmatic EGFR/ErbB1 with the
increased risk of recurrent tumor. Nuclear positivity for EGF
and EGFR/ErbB1 was demonstrated to be a feature of both
follicular adenomas and follicular carcinomas [53, 54].
The role of the ErbB2 proto-oncogene in thyroid car-
cinoma has been controversially discussed. It has been
reported that high levels of ErbB2 mRNA expression cor-
related with lymph node metastasis in papillary carcinoma
[45]. Studies by Utrilla et al. [55] and Haugen et al. [56]
showed that there are marked differences in the pattern of
ErbB2 immunoreactivity depending on the tumor type. The
investigators demonstrated positivity for papillary carcino-
mas and negativity for follicular adenomas and follicular
carcinomas, but they showed controversial results about
medullary carcinomas. Moreover, ErbB2 was not detected in
papillary carcinomas by immunohistochemistry [57]. Some
studies investigated ErbB2 correlation with prognosis. Sugg
et al. [58] found ErbB2 staining correlation with degree of
differentiation, while Gumurdulu et al. [59] demonstrated
that further investigations on ErbB2 role in thyroid tumors
are required for determination of prognosis. Other studies
have associated cytoplasmatic reactivity with patient’s sex in
tumor [60] or with development of metastasis [61].
Few studies analyzed all ErbB family members and their
implication in thyroid tumors. Wiseman et al. [62] showed
that EGFR/ErbB1, ErbB2, ErbB3, and ErbB4 were expressed
in 76%, 2%, 57%, and 73% of differentiated thyroid carcino-
mas analyzed (90 cases of papillary and 6 cases of follicular
carcinomas examined), respectively. Moreover, EGFR/ErbB1
and ErbB3 showed significantly increased expression, while
ErbB4 showed significantly decreased expression in these
tumors compared with benign thyroid lesions. ErbB3 expres-
sion correlated with the presence of lymph node metastases,
tumor type, and higher N stage; the expression of ErbB4
correlated with lower T stage. Kato et al. [63] demonstrated
that the transcription level of ErbB2 and ErbB3 genes was
increased in papillary carcinomas compared to normal
tissues, suggesting that the expression of an ErbB2-ErbB3
heterodimer may correlate with the aggressiveness of a thy-
roid tumor. Interestingly, coexisting protein overexpression
of EGFR/ErbB1, ErbB2, ErbB3, and ErbB4was demonstrated
in 64% of papillary thyroid carcinomas providing numerous
possibilities for functional receptor interactions [64].
5. TGF-β Effects on Thyroid Cell Physiology
TGF-β is synthesized as an inactive precursor that can be
activated by different proteases produced by thyrocytes.
Its expression is upregulated during TSH-induced thyroid
hyperplasia in rats, suggesting that an increased local expres-
sion of TGF-β1, during thyroid hyperplasia, may contribute
to the temporal stabilization of goiter size [65]. TGF-β
signalling is propagated via cell surface serine/threonine
kinases, TGF-β type I receptor (TβRI) and TGF-β type II
receptor (TβRII). Both receptors are expressed on thyrocytes
at equimolar amount [66] and, upon ligand binding by
type II receptor, TβRI is recruited to an heteromeric com-
plex and phosphorylated by TβRII, thus activating its ser-
ine/threonine kinase in order to phosphorylate the transcrip-
tion factors R-Smads (Smad2 and Smad3). The phosphory-
lated Smad2 or Smad3 associate with the common partner
Co-Smad, Smad4, forming complexes that accumulate in the
nucleus, where they regulate target genes expression either by
interacting with other transcription factors and coactivators
or corepressors or by directly binding to defined sequences in
the promoter [67]. In contrast to R-Smads and Co-Smad, the
Inhibitory Smads (I-Smads), including Smad6 and Smad7,
bind to TβRI and compete with R-Smads for activation by
TβRI resulting in the inhibition of TGF-β signalling [68, 69].
A Smad ubiquitin regulatory factor 1 (Smurf1), being a
HECT-type E3 (Homologous to the E6-AP C Terminus)
ubiquitin ligase, interacts with inhibitory Smad7 and induces
cytoplasmic localization of Smad7. Smurf1, then, associates
with TβRI and enhances the turnover of this receptor [70]
(Figure 2).
TGF-β is the important negative regulator of thyrocyte:
it antagonizes the mitogenic effects of the main growth
factors in cultured cells of human [65, 71], dog [72], pig
[73], and rat origin [4, 74]. TGF-β delays progression during
the mid–late G1 phase by directly controlling cyclin D1-3
levels and preventing the relocalization of p27/kip1 inhibitor
from cyclin E/cdk2 to cyclin D3/cdk4 complexes [72, 74].
TGF-β has been shown to downregulate the expression of
thyroid-specific genes in the majority of species. The iodide
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Figure 2: Intracellular signal transduction of TGF-β signalling. TGF-β ligand binds to TβRI and TβRII to constitute active heterodimers
that possess serin-threonin kinase activity. Activated TβRI phosphorylates Smad2 and Smad3, which in turn form a complex with Smad4.
Smad2 or Smad3/Smad4 complex translocates into the nucleus where interacts with other DNA-binding transcription factors, coactivators
and corepressors, regulating the transcription of target genes.
trapping is inhibited in rat thyroid cells by blocking the
protein kinase A (PKA) pathway, but not the PKA-induced
DNA synthesis [75]. Moreover, we have demonstrated that
the overexpression of ErbB2 in FRTL-5 cells, responsible
of the resistance to the inhibitory action of TGF-β on cell
proliferation, does not affect the inhibition of iodide uptake
caused by TGF-β [66]. This effect was likely due in part to
the inhibition of the expression of NISmRNA and its protein
[76, 77] and in part to the inhibition of the expression
and activity of the Na+/I- ATPase, an enzyme that plays
a key role in iodide uptake [78]. Similar responses have
also been observed in porcine cell cultures, where TGF-β
inhibits iodide uptake and metabolism, cAMP formation,
and T4 release [41]. In human thyroid primary cultures,
TGF-β inhibits most effects of cAMP on gene expression
[79]. The rat thyroid cell lines represent a good model to
study the TGF-β action in regulating the TG expression
respect to porcine thyroid follicular cells where, TGF-β has
no effect [80]. In the FRTL-5 rat thyroid epithelial cell
line, the addition of TGF-β inhibits Pax8 mRNA causing
a decreased formation of Pax8/DNA complexes, both with
or without the addition of TSH that is responsible of the
TGFβ1-induced suppression of TG gene expression [81]. In
the same cells, it has been demonstrated that the inhibition
of TG biosynthesis and TSHR expression by TGF-β1 could
be counterbalanced by blocking the nuclear translocation of
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Smad2 and Smad4 [82]. Instead, Smad3 has a key role in the
reduction of NIS expression, because its physical interaction
with Pax8 in turn diminishes Pax8 binding to DNA sequence
involved in the regulation of NIS [83].
In porcine thyroid cells cultured in suspension, TGF-β
counteracts TSH positive effect on folliculogenesis causing
an inversion of cell polarity [84]. The ability of TGF-β to
modulate cytoskeleton organization and extracellular matrix
protein distribution has been demonstrated not only in
porcine thyroid cells, where it stimulates the expression
of plasminogen activator inhibitor-1 (PAI-1), clusterin,
trombospondin-1 [80, 85, 86], but also in rat thyroid cells
[87]. Finally, in the same cellular model TGF-β1 inhibits
the major histocompatibility complex (MHC) class I by
regulating two elements at the transcription start site of the
flanking region and increases the downstream regulatory
element (DRE) binding of an ubiquitously expressed Y-box
protein, termed TSEP-1 (TSHR suppressor element-binding
Protein-1), an important suppressor of the TSHR and of
MHC class I and class II expression [88]. TGF-β1 stimulates
monocyte chemoattractant Protein-1 (MCP-1) and colony-
stimulating factor (CSF) [89], as well as endothelin and its
receptors in human thyroid follicular cells [90].
Therefore, it can be concluded that TGF-β exerts an
important effect on thyroid cells in all the species tested,
inhibiting the proliferation and function and modulating
extracellular matrix (ECM) formation.
6. Role of TGF-β in Thyroid Cancer
The inhibition of cellular proliferation is one of the primary
action of the TGF-β signalling. This factor is involved in the
regulation of other numerous cellular functions as embryo-
genesis, differentiation, apoptosis, angiogenesis, immuno-
suppression, and wound-healing process [91]. Given the
multifunctional role of TGF-β, any aberration of its normal
signalling cascade may have wide-ranging pathologic conse-
quences. Yet, paradoxically, TGF-β also modulates processes
such as cell invasion and microenvironment modification
that cancer cells may exploit to their advantage. Conse-
quently, the output of a TGF-β response is highly contextual
throughout development, across different tissues, and also in
cancer [92].
Thyroid cancer incidence has significantly increased
during the past decades [93], and it has become one of the
ten leading cancer types in females being more frequent
than ovarian, urinary, bladder, or pancreas cancer [94].
Although the majority of thyroid cancers have an excellent
prognosis, there are a small percentage of cases that show
an extensive local invasion and distant metastases, which
frequently do not respond to standard treatments and have a
worsened prognosis. The genetic basis for the initiation and
development of the common type of thyroid cancer, papillary
thyroid carcinoma (PTC), is well characterized. It has been
demonstrated that the activation of oncogenes like RAS,
BRAF, RET/PTC, and PI3K/AKT plays an important role in
thyroid tumorigenesis [95]. However, it is also interesting to
underscore the differences among the tumors arising from
the different mutations. Studies in vitro and in vivo have
clearly shown that other oncoproteins, like EGF and TGF-
β, exert their own oncogenic drive, conferring a distinct
biological behaviour on thyroid tumors. The homoeostasis
of growth in differentiated epithelia reflects a critical balance
between the promotion and suppression of cell division. The
thyroid gland is among the most common sites of epithelial
hyperplasia, affecting up to 15% of the adult population,
typically presenting as “sporadic” or multinodular nontoxic
Goiter (MNTG), the hyperplastic gland usually contains
well-defined nodules of varying size, surrounded by a normal
epithelium. A wide range of studies has revealed evidence
for an involvement of several autocrine growth stimulators
and their receptors in the progression of MNTG. Prominent
among these is TGF-β, and a lack of response to TGF-β
inhibitory action in thyroid cells may be responsible for
some cases of MNTG in human cells [71]. In rats, thyroid
hyperplasia induced by iodide deficiency and goitrogen is
accompanied by an increase in TGF-β1 expression and the
arrest of goiter growth after 4 weeks. This surprising result
is thought to reflect a critical role of TGF-β1 in stabilizing
goiter mass [65, 96]. This would suggest that the increase
in TGF-β1 levels observed during goiter induction might
be a mechanism to counteract the goitrogenic effect of
endogenous TSH [65, 97]. Instead, in a group of patients
with either papillary adenomas (n = 14) or carcinomas
(n = 14), not significant changes in blood levels of TGF-β1
have been observed compared to normal controls [98].
Increased expression of TGF-β, NFkB (nuclear factor of
κB), and CDC42, compared to the normal thyroid tissue,
has been demonstrated in a group of human papillary
thyroid carcinomas, analyzed by oligonucleotide microarray
of microscopically dissected intratumoral samples from
central and invasive regions. These data together with
reduced levels of mRNAs encoding proteins involved in cell-
cell adhesion and communication and an overexpression
of vimentin strongly support the hypothesis that the TGF-
β, responsible of epithelial mesenchymal transition (EMT)
induction, increases the tumor invasiveness in papillary
thyroid carcinomas [95].
Perturbations of TGF-β signalling are central to tumori-
genesis and tumor progression. TβRII is commonly inacti-
vated through mutation and loss of heterozygosity (LOH)
in several types of carcinoma [99]. Lazzereschi et al. [100],
have obtained similar results in a series of human thyroid
tumors, from benign lesions (adenomas) to neoplastic
lesions of increasing aggressiveness (papillary and follicu-
lar carcinomas) up to the extremely aggressive anaplastic
tumors. Northern blot analyses demonstrated a statisti-
cally significant reduction (about 2-3-fold less) of TβRII
expression in papillary thyroid carcinomas in comparison
with the respective healthy tissues. Immunostaining of the
formalin-fixed sections with specific anti-TβRII antibodies
substantiates these data, clearly demonstrating that the
greatest reduction in TβRII immunoreactivity was found
in the highly malignant, undifferentiated anaplastic thyroid
tumors. A comparative study performed in different types
of epithelial thyroid carcinomas of patients from different
regions of the world demonstrated a strong decrease of TβRII
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expression in follicular cancer of patients from China, Japan,
and USA (50%, 55%, and 90% respectively). In papillary
thyroid carcinoma TβRII was decreased in 75%, 77% and
96% of patients from Japan, China, and USA, respectively.
Finally, in undifferentiated cancer, the reduction of TβRII
expression was observable in 83% of patients from USA and
in 100% of patients from China [101].
Inactivating mutations in Smad2 and 4 are frequently
found in some cancers [102]. In a group of 20 follic-
ular thyroid neoplasms, classified as 11 adenomas and
9 minimally invasive follicular carcinomas, according to
current pathological criteria, Smad2 expression investigated
by immunohistochemistry has been lost, while TβRII expres-
sion was lost in 78%. These data indicate that the downreg-
ulation of TβRII remains the major consistent abnormality
in thyroid carcinomas that may be used to differentiate
minimally invasive carcinomas from adenomas, while the
downregulation of Smad2 could be another mechanism
by which carcinomas become independent from TGFβ–
mediated growth inhibition [103].
The tumor suppressor role of TβRII has been demon-
strated in vitro in a model of K-ras transformed rat thyroid
cells, where the overexpression of TβRII induces not only
a partial reversion of malignant phenotype restoring the
sensitivity to TGF-β, but also a significant reduction in spon-
taneous and lung artificial metastases when transplanted in
athymic nude mice [104]. In this model, the overexpression
of TβRII is essential to reduce the invasive potential and
to modulate the adhesive and migratory cell behaviours
by controlling the integrin functions rather than integrin
receptor expression [105]. The inhibitory action of TGF-β1
on cellular migration, invasion, and adhesion is present in a
set of human PTC and follicular thyroid carcinoma (FTC)
cell lines, while inhibition of TGFβ-induced cell growth
is maintained only in FTC cell lines [106]. Other authors
demonstrated that in human papillary thyroid carcinoma
cell line TPC-1, these effects are probably due to the lower
level of Smads 2, 3, and 4 associated to an increase in Smad7
expression [107]. Otherwise, the altered expression of TGF-
β pathway proteins not always is responsible of resistance to
the TGF-β action. A human anaplastic carcinoma cell line,
despite the activity of receptors signalling, Smad2 phospho-
rylation and nuclear translocation of Smad2/4 complexes, is
strongly resistant to the TGF-β action, suggesting that other
signalling mechanisms might be related to the escape from
TGF-β sensitivity [108].
Sensitivity to TGF-β is impaired in thyroid tumors and
escape from TGF-β action is actively selected during thyroid
tumor development. Destruction of the TGF-β signalling
at the level of Smad genes is common in human carcino-
mas, the deficiencies of Smad4 have been hypothesized to
underlie TGF-β resistance of tumor cells and to strongly
accelerate the malignant progression of neoplastic lesions
initiated by other oncogenic stimuli [92]. Lazzereschi et
al. [109] showed, for the first time, the mutational and
the expression status of Smad4 in a consistent number of
thyroid tumors of different histotypes, demonstrating the
high frequency of Smad4 abnormalities (27%) in thyroid
tumors, comparable only with Smad4 mutation frequency in
tumors arising from the gastrointestinal tract, both sporadic
and inherited. The high frequency of alterations in Smad4
sequence led the authors to propose that these changes may
constitute a nearly and frequent event in thyroid tumors
natural history. Smad4 inactivation in tumors is generally
a late event linked to progression to overt carcinoma. In
human papillary thyroid cell lines, TPC-1 and BCPAP,
it has been recently demonstrated a strong reduction in
the level of SMAD4 protein, which is responsible for
an alteration of TGF-β signalling and for some of the
TGF-β-mediated biological effects. The overexpression of
Smad4, restoring TGF-β signal transduction, determines a
significant increase of antiproliferative response to TGF-
β, reduces the invasive behaviour of these cells as well
as is responsible of a significant increase of E-cadherin
expression, indicating that the level of SMAD4 is a critical
regulator of these processes. To remark the important role
of SMAD4 in thyroid carcinogenesis contributes also the
finding obtained by immunohistochemistry that 7 out of
23 (30%) PTC tumor samples, including 1 case of follicular
variant of PTCs, present a weak and focal intensity of SMAD4
staining compared to normal tissue from the opposite lobe
[110].
The stability of TβRI represents an important regulatory
mechanism for TGF-β signalling both in cell culture studies
and in vivo models. TGF-β receptors are ubiquitinated and
degraded through the action of several cooperating protein
complexes containing E3 ligases as well as other important
regulators of protein degradation. The I-Smads regulate
many of these complexes, orchestrating both ubiquitination
and de-ubiquitination [111]. The levels of Smurf1 and
Smad7 are overexpressed in the anaplastic thyroid carcinoma
cell line [112], and an increase of SMAD7 expression
has been found in a group of papillary and follicular
carcinomas with respect to benign pathologies, indicating
SMAD7 as another SMAD involved in thyroid tumorigenesis
[113].
It is known that TGF-β’s role in human cancer appears
both complex and context depended. Depending on the
tumor type and the stage of tumor progression, it can exercite
strong tumor suppressive or tumor-promoting functions.
More recently, it has been demonstrated that also in thyroid
cells, as well as in the skin tumors, or in metastatic colon
cancer [114], TGF-β can acts as tumor-promoting factor.
The expression of BRAFV660E, in normal rat thyrocytes and
in fifty cases of human PTC determines a reduction of NIS
expression and an increase of TGF-β secretion, suggesting an
hyperactivation of TGF-β signalling, responsible of the pro-
tumorigenic activity [115].
The aberrant microRNA (miR) expression, involved in
the cell growth suppressive function, has been demon-
strated in a large number of follicular thyroid neoplasias
[116]. More recently, a new important function of TGF-
β, involving the regulation of expression of miR levels
(miR-200 and miR-30), has been discovered in human
anaplastic thyroid carcinoma (ATC). ATCs represent a more
aggressive type of thyroid cancer arising from mesenchymal
de-/transdifferentiation of epithelial thyroid cells that rapidly
invade the adjacent tissue. The main function of miR-200
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and miR-30 is to negatively regulate the EMT process in
follicular cells. The low levels of miR-200 and miR-30 in
ATCs respect to that observed in thyroid normal tissues, in
PTCs or in FTCs, strongly suggest that the invasive potential
of ATC is due to enhancement of EMT process. In addition,
it has been demonstrated that the reduction of miR-200 and
miR-30 in these carcinomas is caused by a strong activation
of TGF-β signalling due to an upregulation of TβRI and
Smad2. Therefore, the authors not only propose a novel
molecular panel to identify ATCs, but also they suggest
the inhibition of TGF-β signalling represent a new likely
approach for the treatment of these carcinomas [117].
7. Growth Factors Cross-Talk in Thyroid:
Role of TGF-β and EGF Systems in
the Regulation of Thyroid Growth
Complex and apparently redundant interactions between
hormones and growth factors regulate thyroid cell pro-
liferation and differentiation. However, information about
the cross-talk between different growth factors that regulate
thyroid cell growth is limited. Ariga et al. [118] studied
the signalling pathway through which the synergistic actions
between IGF-I and TSH are mediated in FRTL-5 cells. Also,
TGF-β1 and IGF-I appear to interact and have opposite
effects on the growth of rat thyroid cells [75]. In particular,
TGF-β1 attenuates IGF-I-stimulated MAPK phosphoryla-
tion through inhibition of IRS-1 (insulin receptor substrate-
1) tyrosine phosphorylation, IRS-1/Grb2/Sos complex for-
mation and CrkII tyrosine phosphorylation thus leading to
the suppression of FRTL-5 cell growth [119]. ErbB ligands
and ErbB receptors provide a complex and multilayered
network of signalling that is deregulated in many human
tumors. However, several are the causes and mechanisms
of uncontrolled signalling by ErbB receptors suggesting that
differences exist within the ErbB family in the mechanism
of regulation but also in the cross-talk with other growth
factors.
TGF-β is involved in two opposing activities: it is able to
function as a growth inhibitor at early stages of carcinogene-
sis and as a growth promoter at later stages of neoplasia when
tumor cells that have developed the capability to bypass the
tumor inhibitor function of TGF-β, paradoxically, may use
it for tumor progression by means of multiple mechanisms.
Overexpression of TGF-β ligands has been reported in
most cancers [120] and correlates with markers of a more
metastatic phenotype and/or a poor patient outcome. This
dual role of TGF-β is believed to result from molecular
cross-talk with a complex network of signalling pathways
involving either direct effects on tumor cells or paracrine
effects on other cells [121]. Several reports provided evidence
that TGF-β can collaborate with EGF/ErbB receptors system.
Indeed, it has been shown that Smads proteinsmay cross-talk
with mitogenic growth-factor signalling through receptor
tyrosine kinase-inducedMEK/MAPKprotein kinases both in
a synergistic (MEK1-induced Smad2 phosphorylation) [122]
or an antagonistic interplay (MAPK-induced Smad1 phos-
phorylation) [123, 124]. In tumors, ErbB receptors and their
ligands promote growth and confer apoptosis resistance, thus
overcoming TGF-β1 growth inhibition and apoptotic effect.
Indeed, in rat hepatocytes an autocrine loop of TGF-β in
cells that have undergone EMT, induces an upregulation of
EGFR/ErbB1 ligands by promoting their shedding through
the activation of ADAM17 (a disintegrin andmetalloprotease
17) and thus allowing some cells to escape from TGFβ-
induced pro-apoptotic effect [125, 126]. A further mech-
anistic insight on the conversion of the function of TGF-
β from tumor suppressor to tumor promoter has been
provided by the evidence that the EGF signalling pathway
may enhance TGF-β responses. EGF increases the stability
of TβRII thus preventing full loss of TβRII expression in
late stage of cancers, and thereby permits some of the direct
oncogenic behaviour of TGF-β during tumor progression
[127]. Uttamsingh et al. [128] showed that in conjunction
with EGF, TGF-β1 helps to augment migration, invasion
and anchorage-independent growth of intestinal epithelial
cells, in agreement with reports indicating that activation
of TGF-β signalling promotes pulmonary metastasis of
mammary tumors in neu transgenic mice [129]. Moreover,
the elevated and prolonged activation of ERK/MAPK and
its requirement for EGF and TGFβ1-induced EMT and
migration/invasion of intestinal cells is in agreement with
that between ErbB2 and TGF-β1 in mammary epithelial
cells [130]. In fibroblasts, TGF-β induces the upregulation
of ErbBs ligands and activation of cognate receptors via the
canonical Smad pathway, thus allowing the induction of
fibroblast cell morphologic transformation and anchorage-
independent growth [131].
Contrasting to this plethora of data on cross-talk between
EGF and TGF-β1 signals, there are very few results in the
literature relating the interconnection between EGF and
TGF-β signalling pathways in thyroid cancer cells.
Rat thyroid epithelial cells overexpressing the ErbB2
proto-oncogene are not transformed in vitro but no longer
depend on TSH for cell growth and become resistant to
the growth inhibitory effects of TGF-β1, thus suggesting
that ErbB2 proto-oncogene, when overexpressed, is able to
interfere and cross-talk with growth factors that control in
a positive and negative manner the thyroid cell proliferation
[132]. Using collagen gel-cultured porcine follicles, Nilsson
et al. [133] demonstrated that the morphoregulatory effects
of EGF are highly influenced by TGF-β1. In particular,
TGF-β1 inhibits EGF-induced thyrocytes proliferation, but
it synergizes with EGF in the stimulation of cell migration.
This latter effect could be due to the known role of TGF-
β1 to regulate the cell-matrix interactions, by stimulating
the synthesis of extracellular matrix components, inhibit-
ing proteases and inducing changes of integrin synthesis.
However, contrasting to these results, TGF-β1 inhibited both
EGF-induced mitogenesis and motogenesis in rabbit corneal
epithelial cells [134] indicating that the modulation by TGF-
β1 of EGF responses differs among epithelial cell types.
Moreover, in a follicular thyroid cancer cell line lacking
endogenous TSHR, EGF, and TGF-β have been shown
to enhance VEGF (vascular endothelial growth factor)
secretion. Since the loss of the TSHR is characteristic of
anaplastic thyroid cancer, which usually exhibits significantly
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increased VEGF expression and a high degree of angiogenesis
compared with differentiated thyroid cancer, the finding
of VEGF stimulation by EGF and TGF-β, highlights the
important role of these growth factors in thyroid tumor
progression and aggressiveness [135]. Preliminary data from
our laboratory demonstrate that cotreatment with EGF and
TGF-β1 results in opposite effects in human thyroid cancer
cell lines. Indeed, TGF-β1 inhibits EGF-mediated migra-
tion in invasion/wound healing assay, while a synergistic
effect between TGF-β1 and EGF is observed in anchorage-
independent growth assay. These findings demonstrate that
cell invasion and anchorage-independent growth capability
involve different factors and molecular mechanisms (Min-
cione G. et al., unpublished results).
8. Conclusions
The findings described in this paper support the hypothesis
that a network formed by the EGF/ErbBs system and TGF-
β pathway is involved in the pathogenesis and progression
of thyroid tumors. Further understanding of the complexity
of cross-talk between these pathways in thyroid disease
related to gain of function of ErbB, inactivation of growth
suppression function, or activation of tumor promoter
activity of TGF-β1 will offer a broader spectrum of points of
intervention and will lead to continued advances in thyroid
cancer treatment.
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